Il s’agit d’un employé asymptomatique qui a reçu un résultat positif en arrivant sur le site minier, a fait savoir Baffinland dans un communiqué de presse, jeudi soir.
L’employé se trouve actuellement en isolement. L’entreprise indique avoir lancé des procédures de recherches de contacts pour déterminer s’il y a des risques possibles de transmission. Read More.
Rio Tinto has made arrangements for thorough COVID-19 testing for its employees. The step was taken as a precautionary measure.
In order to protect its workers, Rio Tinto will have the facility of COVID-19 testing at Diavik diamond mine in Northwest Territories, Canada. The step was taken as a precautionary measure.
One on-site laboratory has been installed at Diavik, by not for profit public health specialist GuardRX. Read More
WHEN THE LATE Bob Simon interviewed Gary Kobinger for 60 Minutes in 2015, Kobinger was working principally in a space suit in a special clean room behind bulletproof glass. At the time, he was a top virologist at Canada’s National Microbiology Lab, where he became a key player in the development of the early Ebola treatment ZMapp, as well as an Ebola vaccine. Now he’s the director of the Infectious Disease Research Center at the Université Laval in Quebec City, his hometown. His lab helped with the early development of Inovio Pharmaceuticals’ Zika vaccine in 2017.
Today, Kobinger is among hundreds of scientists worldwide working on potential Covid-19 vaccines; he is working with Inovio and Medicago, another drug company. WIRED talked with Kobinger by phone last week. The conversation has been condensed and edited.
Continue reading the full interview with WIRED.